Pomalidomide and the growing role of immunomodulatory agents in the treatment of myelofibrosis

Kathryn B. Bollin, Holly L. Geyer, Ruben A. Mesa

Research output: Contribution to journalArticle

Abstract

Introduction: Myelofibrosis (MF) is a myeloid malignancy that may arise de novo as primary MF or antecedent to essential thrombocythemia or polycythemia vera. Recent discoveries in the pathogenesis contributing to MF symptoms have led to various targeted therapies including the promising immunomodulator, pomalidomide (POM). Areas covered: Treatments for MF are directed at alleviating the burden of symptoms and transfusion dependence. Clinical trials investigating effects of thalidomide derivatives and JAK2 inhibitors on symptoms and cytopenias have demonstrated variable improvements. POM (Pomalyst®), a second-generation immunomodulatory agent (IMiD; Celgene Corp.®), has demonstrated efficacy in mediating the regenerative cellular propensities observed in autoimmune-mediated disorders, solid tumors, and hematological malignancies via its anti-inflammatory, antiangiogenic, and immunomodulatory effects. Studies of POM in MF have demonstrated efficacy in achieving transfusion independence and improving cytopenias while proving more tolerable than thalidomide and lenalidomide. Results from an active Phase III randomized trial are eagerly awaited. In this article, we review the application of IMiDs in the treatment of MF and discuss the emerging role of POM as a potential armament against MF symptoms. Search methodology included a comprehensive review of MEDLINE articles and annual meeting abstracts from the 2010-2013 American Society of Hematology and American Society of Clinical Oncology publications. Expert opinion: POM monotherapy improves cytopenias in MF with fewer side effects than other immunomodulators. POM in combination with JAK2 inhibitors and other agents may prove beneficial in targeting the complex aberrant signaling pathways inherent to MF.

Original languageEnglish (US)
Pages (from-to)539-547
Number of pages9
JournalExpert Opinion on Orphan Drugs
Volume1
Issue number7
DOIs
StatePublished - 2013

Fingerprint

Primary Myelofibrosis
Thalidomide
Immunologic Factors
Essential Thrombocythemia
pomalidomide
Polycythemia Vera
Expert Testimony
Hematologic Neoplasms
MEDLINE
Publications
Neoplasms
Anti-Inflammatory Agents
Clinical Trials

Keywords

  • Essential thrombocythemia
  • Immunomodulatory agents
  • Myelofibrosis
  • Myeloproliferative neoplasms
  • Polycythemia vera
  • Pomalidomide
  • Primary myelofibrosis

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Health Policy
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Pomalidomide and the growing role of immunomodulatory agents in the treatment of myelofibrosis. / Bollin, Kathryn B.; Geyer, Holly L.; Mesa, Ruben A.

In: Expert Opinion on Orphan Drugs, Vol. 1, No. 7, 2013, p. 539-547.

Research output: Contribution to journalArticle

Bollin, Kathryn B. ; Geyer, Holly L. ; Mesa, Ruben A. / Pomalidomide and the growing role of immunomodulatory agents in the treatment of myelofibrosis. In: Expert Opinion on Orphan Drugs. 2013 ; Vol. 1, No. 7. pp. 539-547.
@article{87baa78a44a34104b4d37aeef485fe70,
title = "Pomalidomide and the growing role of immunomodulatory agents in the treatment of myelofibrosis",
abstract = "Introduction: Myelofibrosis (MF) is a myeloid malignancy that may arise de novo as primary MF or antecedent to essential thrombocythemia or polycythemia vera. Recent discoveries in the pathogenesis contributing to MF symptoms have led to various targeted therapies including the promising immunomodulator, pomalidomide (POM). Areas covered: Treatments for MF are directed at alleviating the burden of symptoms and transfusion dependence. Clinical trials investigating effects of thalidomide derivatives and JAK2 inhibitors on symptoms and cytopenias have demonstrated variable improvements. POM (Pomalyst{\circledR}), a second-generation immunomodulatory agent (IMiD; Celgene Corp.{\circledR}), has demonstrated efficacy in mediating the regenerative cellular propensities observed in autoimmune-mediated disorders, solid tumors, and hematological malignancies via its anti-inflammatory, antiangiogenic, and immunomodulatory effects. Studies of POM in MF have demonstrated efficacy in achieving transfusion independence and improving cytopenias while proving more tolerable than thalidomide and lenalidomide. Results from an active Phase III randomized trial are eagerly awaited. In this article, we review the application of IMiDs in the treatment of MF and discuss the emerging role of POM as a potential armament against MF symptoms. Search methodology included a comprehensive review of MEDLINE articles and annual meeting abstracts from the 2010-2013 American Society of Hematology and American Society of Clinical Oncology publications. Expert opinion: POM monotherapy improves cytopenias in MF with fewer side effects than other immunomodulators. POM in combination with JAK2 inhibitors and other agents may prove beneficial in targeting the complex aberrant signaling pathways inherent to MF.",
keywords = "Essential thrombocythemia, Immunomodulatory agents, Myelofibrosis, Myeloproliferative neoplasms, Polycythemia vera, Pomalidomide, Primary myelofibrosis",
author = "Bollin, {Kathryn B.} and Geyer, {Holly L.} and Mesa, {Ruben A.}",
year = "2013",
doi = "10.1517/21678707.2013.818918",
language = "English (US)",
volume = "1",
pages = "539--547",
journal = "Expert Opinion on Orphan Drugs",
issn = "2167-8707",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Pomalidomide and the growing role of immunomodulatory agents in the treatment of myelofibrosis

AU - Bollin, Kathryn B.

AU - Geyer, Holly L.

AU - Mesa, Ruben A.

PY - 2013

Y1 - 2013

N2 - Introduction: Myelofibrosis (MF) is a myeloid malignancy that may arise de novo as primary MF or antecedent to essential thrombocythemia or polycythemia vera. Recent discoveries in the pathogenesis contributing to MF symptoms have led to various targeted therapies including the promising immunomodulator, pomalidomide (POM). Areas covered: Treatments for MF are directed at alleviating the burden of symptoms and transfusion dependence. Clinical trials investigating effects of thalidomide derivatives and JAK2 inhibitors on symptoms and cytopenias have demonstrated variable improvements. POM (Pomalyst®), a second-generation immunomodulatory agent (IMiD; Celgene Corp.®), has demonstrated efficacy in mediating the regenerative cellular propensities observed in autoimmune-mediated disorders, solid tumors, and hematological malignancies via its anti-inflammatory, antiangiogenic, and immunomodulatory effects. Studies of POM in MF have demonstrated efficacy in achieving transfusion independence and improving cytopenias while proving more tolerable than thalidomide and lenalidomide. Results from an active Phase III randomized trial are eagerly awaited. In this article, we review the application of IMiDs in the treatment of MF and discuss the emerging role of POM as a potential armament against MF symptoms. Search methodology included a comprehensive review of MEDLINE articles and annual meeting abstracts from the 2010-2013 American Society of Hematology and American Society of Clinical Oncology publications. Expert opinion: POM monotherapy improves cytopenias in MF with fewer side effects than other immunomodulators. POM in combination with JAK2 inhibitors and other agents may prove beneficial in targeting the complex aberrant signaling pathways inherent to MF.

AB - Introduction: Myelofibrosis (MF) is a myeloid malignancy that may arise de novo as primary MF or antecedent to essential thrombocythemia or polycythemia vera. Recent discoveries in the pathogenesis contributing to MF symptoms have led to various targeted therapies including the promising immunomodulator, pomalidomide (POM). Areas covered: Treatments for MF are directed at alleviating the burden of symptoms and transfusion dependence. Clinical trials investigating effects of thalidomide derivatives and JAK2 inhibitors on symptoms and cytopenias have demonstrated variable improvements. POM (Pomalyst®), a second-generation immunomodulatory agent (IMiD; Celgene Corp.®), has demonstrated efficacy in mediating the regenerative cellular propensities observed in autoimmune-mediated disorders, solid tumors, and hematological malignancies via its anti-inflammatory, antiangiogenic, and immunomodulatory effects. Studies of POM in MF have demonstrated efficacy in achieving transfusion independence and improving cytopenias while proving more tolerable than thalidomide and lenalidomide. Results from an active Phase III randomized trial are eagerly awaited. In this article, we review the application of IMiDs in the treatment of MF and discuss the emerging role of POM as a potential armament against MF symptoms. Search methodology included a comprehensive review of MEDLINE articles and annual meeting abstracts from the 2010-2013 American Society of Hematology and American Society of Clinical Oncology publications. Expert opinion: POM monotherapy improves cytopenias in MF with fewer side effects than other immunomodulators. POM in combination with JAK2 inhibitors and other agents may prove beneficial in targeting the complex aberrant signaling pathways inherent to MF.

KW - Essential thrombocythemia

KW - Immunomodulatory agents

KW - Myelofibrosis

KW - Myeloproliferative neoplasms

KW - Polycythemia vera

KW - Pomalidomide

KW - Primary myelofibrosis

UR - http://www.scopus.com/inward/record.url?scp=84896739099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896739099&partnerID=8YFLogxK

U2 - 10.1517/21678707.2013.818918

DO - 10.1517/21678707.2013.818918

M3 - Article

AN - SCOPUS:84896739099

VL - 1

SP - 539

EP - 547

JO - Expert Opinion on Orphan Drugs

JF - Expert Opinion on Orphan Drugs

SN - 2167-8707

IS - 7

ER -